The Australian federal health department is urging healthcare professionals to exercise significant caution when utilizing artificial intelligence-powered medical scribing tools. This warning comes as regulators examine whether stronger safeguards are necessary for one of the fastest-growing technologies in modern medicine, according to a report by The Guardian. While these AI systems record and summarize doctor-patient conversations into clinical notes—reducing administrative burdens—the government warns that rapid adoption has outpaced oversight, raising critical questions regarding patient privacy, informed consent, and medical record accuracy.
Surging Adoption Outpaces Regulatory Oversight
The urgency of the warning is underscored by rapidly increasing usage rates. An online survey conducted by the Royal Australian College of General Practitioners (RACGP) revealed that the proportion of Australian doctors using AI scribes nearly doubled, rising from 22 percent in August 2024 to 40 percent by November 2025. Technology providers claim their platforms have processed hundreds of millions of consultations globally over the past 18 months.
However, briefing papers prepared for Senate Estimates in February 2026 describe the technology as having "little oversight." Officials noted that some AI scribes are marketed as operating outside existing medical device regulations despite being used directly in clinical settings. The health department acknowledges that while these tools could improve clinician productivity and help reduce burnout, they inherit limitations common to large language models. Errors in transcription or summarization pose potential risks to patient safety, clinical accountability, and the integrity of Australia’s digital health infrastructure.
Privacy Concerns and Data Security Risks
A major focus of the regulatory scrutiny involves data privacy and security. Officials found that some providers promote their products as compliant with privacy standards while offering limited transparency regarding how patient information is processed. In several instances, healthcare providers may not realize that sensitive patient data is being transmitted to cloud servers located outside Australia, potentially exposing medical information to additional risks.
"The government has identified significant variations in how clinics obtain permission before recording consultations," officials noted during the review process."
Fragile Consent and Fragmented Regulation
Patient consent remains a critical area of concern. The government found that meaningful informed consent requires patients to fully understand both the benefits and limitations of AI-assisted documentation. Consumer groups have reported instances where patients were told they would need to find another healthcare provider if they declined to use AI scribes during appointments.
Furthermore, officials questioned marketing claims suggesting AI scribes can increase doctors’ revenue by approximately 30 percent without extending working hours. Such incentives could have broader implications for Australia’s publicly funded Medicare system if higher billing becomes a primary driver for adoption. The regulatory landscape remains fragmented, with oversight shared between the Therapeutic Goods Administration (TGA), the Australian Health Practitioner Regulation Agency (Ahpra), and the Office of the Australian Information Commissioner. The TGA is currently reviewing whether AI scribes should be formally classified as medical devices, with a report expected in the coming months.
